Loading
companiesCompany
Hellenic Oncology Research Group
aka HORG
The Hellenic Oncology Research Group is a Greek non-profit of oncologists and scientists that runs its own cancer trials; in OnCo it leads three phase 3 adjuvant breast cancer trials.
Overview
The Hellenic Oncology Research Group (HORG) describes itself as a non-profit organisation fostering clinical and translational cancer research, whose members are medical oncologists, radiation oncologists, pathologists and scientists; its contact address is Grigoriou Theologou 5, Athens 11471 (horg.gr). No founding year is stated on the pages read. ClinicalTrials.gov names it lead sponsor (OTHER class, with the University Hospital of Crete as collaborator) of three phase 3 trials recorded in OnCo: NCT00431080 and NCT01985724 (sequential FEC-based chemotherapy followed by docetaxel against docetaxel-cyclophosphamide as adjuvant treatment of breast cancer) and NCT00615602 (six against twelve months of adjuvant trastuzumab with docetaxel after FEC). It has no products of its own.
Similar pages
not linked directly; found by shared links- TreatmentLenograstim
Shares Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer, Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer, Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer.
- TreatmentPegfilgrastim
Shares Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer, Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer, Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer.
- TreatmentEpirubicin
Shares Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer, Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer, Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer.
cancers
1trials
3Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast CancerSequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast CancerSix vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer